Ozempic vs Wegovy: Same Drug, Different Label

If you have spent any time researching GLP-1 medicines, you have probably hit the same confusing wall everyone does: people talk about "Ozempic for weight loss" in one breath and "Wegovy for weight loss" in the next, as if they were rivals. Here is the plain truth that cuts through all of it — Ozempic and Wegovy are the same drug. Both are semaglutide, the identical molecule, made by the same company (Novo Nordisk). They are not chemical cousins or competing formulas. They are the same active ingredient sold under two brand names.

So why two names? Because in the United States, a drug's brand, its FDA-approved use, and its insurance coverage are all tied to the specific application the manufacturer filed for. Novo Nordisk took semaglutide through one approval pathway for type 2 diabetes (and branded that Ozempic) and a separate pathway for chronic weight management (branded Wegovy). Same molecule, two labels. Everything that feels different between them flows from that one regulatory fact.

Let's go through exactly what is identical, what genuinely differs, and what that means for you.

The part that's identical: the molecule

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone your body releases after you eat; it prompts insulin release when blood sugar is high, tells your brain you are full, and slows how fast your stomach empties¹. Semaglutide is a long-acting molecule designed to keep those signals switched on, and it does the same thing in your body whether the box says Ozempic or Wegovy. If you want the full mechanism-and-evidence picture, we cover it in Semaglutide: How It Works, Results & Side Effects. (A newer combination, CagriSema, pairs this same semaglutide with a second appetite hormone — see CagriSema vs Wegovy: stronger than semaglutide?.)

Because the active ingredient is the same, the side-effect profile is the same too: mostly gastrointestinal — nausea, vomiting, diarrhea, constipation — worst early and during dose increases, easing over time. A pooled analysis across the SUSTAIN diabetes trials characterized this profile and, notably, found weight loss happened even in people who had no GI side effects, so the queasiness is not the "engine" of the effect¹⁰. Both brands also carry the same boxed warning about thyroid C-cell tumors (from rodent studies) and the same contraindications. The drug is the drug. (The molecule also carries a documented cardiovascular benefit in specific populations — proven at the Wegovy dose in the SELECT trial; we cover it in do Wegovy & Ozempic protect the heart?.)

Difference #1: the FDA-approved indication

This is the big one, and it is the reason both names exist.

Ozempic is approved for type 2 diabetes. Its FDA label indicates it to improve blood sugar control in adults with type 2 diabetes, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease, and to lower the risk of kidney-function decline and cardiovascular death in adults with type 2 diabetes and chronic kidney disease². Notice what is not on that list: weight loss in people without diabetes. Ozempic's diabetes and cardiovascular evidence is large — the SUSTAIN-6 outcomes trial showed it reduced major cardiovascular events in people with type 2 diabetes⁴, and head-to-head against dulaglutide (SUSTAIN 7) it produced greater reductions in blood sugar and weight⁵.

Wegovy is approved for weight management. Its FDA label indicates it for chronic weight reduction in adults with obesity (or overweight plus at least one weight-related condition) and in adolescents 12 and older with obesity, to reduce cardiovascular risk in adults with established heart disease and obesity/overweight, and — added more recently — for noncirrhotic MASH (a form of fatty-liver disease) with moderate-to-advanced fibrosis³. The pivotal weight-loss evidence is the STEP 1 trial, a 68-week randomized study in which once-weekly semaglutide 2.4 mg produced a large average reduction in body weight versus placebo⁶. (How those trial averages line up with what people actually report is the focus of our Wegovy reviews synthesis.) And the SELECT trial showed Wegovy-dose semaglutide cut major cardiovascular events in people with obesity and heart disease but without diabetes — a benefit beyond weight loss alone⁷.

So when someone says "Ozempic for weight loss," what they usually mean is a doctor prescribing the diabetes brand off-label to someone who wants to lose weight. It can work — it is the same molecule — but it is technically off-label use, and that distinction matters for insurance (more below).

Difference #2: the maximum dose

Because the two brands were studied and approved for different goals, they top out at different doses.

• •Ozempic (diabetes) is titrated from 0.25 mg weekly up to a maximum maintenance dose of 2 mg once weekly².
• •Wegovy (weight management) is titrated higher — up to a 2.4 mg weekly maintenance dose, and the current label now also offers a higher-dose option (Wegovy HD, up to 7.2 mg weekly) for adults who have tolerated 2.4 mg and need additional weight loss³.

Both brands start at the same gentle 0.25 mg and step up about every four weeks, because the slow ramp is what keeps nausea tolerable — the STEP 1 trial used exactly that gradual escalation⁶. The practical upshot: Wegovy can reach a higher dose than Ozempic, which is part of why the weight-loss brand can drive somewhat larger average loss than the diabetes brand's ceiling. But the difference is one of dose and approval, not of a different or "stronger" drug — we break down that dose-driven gap in Ozempic dosing for weight loss. We walk through the full titration ladder in Semaglutide Dosing & Side Effects, and map Wegovy's specific 0.25-to-2.4 mg climb in the Wegovy titration schedule.

Difference #3: insurance coverage

Here is where "same drug, different label" hits your wallet hardest. Insurers cover drugs by approved indication, not by molecule.

• •If you have type 2 diabetes, Ozempic is usually the more straightforwardly covered option, because diabetes is its on-label use.
• •If you want a prescription specifically for weight loss, Wegovy is the on-label choice — but many plans still exclude or tightly restrict anti-obesity medications, requiring prior authorization, a documented BMI, or step-therapy.
• •Getting Ozempic prescribed off-label for weight loss often runs into coverage denials, because the plan sees a diabetes drug being used for a non-diabetes purpose.

This is genuinely why two brands exist commercially: they let coverage, pricing, and access be managed separately for two different patient populations. None of it changes the molecule in the pen. For the full picture — prior authorization, the Medicare weight-loss exclusion, TRICARE, and how to handle a denial — see Does Insurance Cover Wegovy or Ozempic?. If coverage is your sticking point, our Wegovy cost guide breaks down the self-pay vials, savings card, GoodRx-type discounts, and the honest caveats on cheaper compounded semaglutide.

Are there formulation differences too?

Functionally they deliver the same medicine, but the pens differ because the dose ladders differ. Ozempic and Wegovy come in their own brand-specific pens calibrated to their own dose schedules, so you cannot mix and match pens between them — you use the device that matches your brand and your current step. The injection technique itself is the same subcutaneous, once-weekly shot in the abdomen, thigh, or upper arm; if you are new to it, see our step-by-step How to Inject Wegovy (the technique applies to Ozempic's pen too). There is also a third semaglutide product — Rybelsus, a daily oral tablet for type 2 diabetes, whose evidence comes from the PIONEER program⁹ — which we compare in Oral vs Injectable Semaglutide.

What about stopping — does the brand change that?

No. Because it is the same molecule, the "what happens when you stop" answer is identical for both. Semaglutide manages weight and metabolic conditions rather than curing them: in the STEP 1 trial extension, people who stopped regained roughly two-thirds of the weight they had lost within a year, with metabolic markers reversing too⁸. The STEP 4 trial showed the flip side — continuing it preserved the loss, while switching to placebo led to regain¹¹. Whether you are on Ozempic or Wegovy, that ongoing-therapy reality is the same. We unpack it in What Happens If You Stop Semaglutide?. Other day-to-day questions also apply equally to both brands — for instance, whether you can drink alcohol on Wegovy or Ozempic.

The honest bottom line

Ozempic and Wegovy are the same drug — semaglutide — wearing two different labels. The differences that matter are regulatory and practical, not chemical: Ozempic is FDA-approved for type 2 diabetes and tops out at 2 mg; Wegovy is FDA-approved for chronic weight management, titrates up to 2.4 mg (with a higher-dose option), and is the on-label choice for weight loss. Insurance follows those approved uses, which is why coverage can feel like the real dividing line. Knowing they are one molecule helps you have a clearer conversation with your prescriber about which brand fits your diagnosis and your coverage. If you are weighing where and how to start, our independent best semaglutide providers guide ranks legitimate options on price and oversight. And if you are moving to or from the tirzepatide drug Zepbound — a genuinely different molecule, unlike these two brands — read switching from Zepbound to Wegovy first, because those doses do not convert one-to-one. For the head-to-head efficacy and side-effect breakdown of those two molecules, see semaglutide vs tirzepatide: which works better?.